FDA D.I.S.C.O.: First Tissue/Site Agnostic Cancer Treatment Approval
FDA experts discuss the first approval of a cancer treatment based on a common biomarker rather primary tumor location.
Media formats available
Completing the pre-test is required to access this content.
Pre-Survey
Completing the pre-survey is required to access this content.
